Icahn Enterprises IEP Pharma — Total Assets
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Icahn Enterprises's pharma — total assets?
- Icahn Enterprises (IEP) reported pharma — total assets of $222M in Q1 2026.
- How has Icahn Enterprises's pharma — total assets changed year-over-year?
- Icahn Enterprises's pharma — total assets decreased by 19.0% year-over-year, from $274M to $222M.
- What is the long-term trend for Icahn Enterprises's pharma — total assets?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — total assets has grown at a -5.4% compound annual growth rate (CAGR), from $1.26B to $1.01B.
- What does pharma — total assets mean?
- The total value of all resources owned or controlled by the pharmaceutical segment, including tangible and intangible assets. This metric provides a comprehensive view of the capital base deployed to support drug development and commercial operations. It serves as a primary indicator of the segment's scale and resource intensity.